Search Videos and More
Symposium
Hematologic Malignancies CME: 2021
The care of patients with hematologic malignancies is evolving rapidly. These video highlights discuss new developments in the diagnosis and treatment of hematologic malignancies presented at the 2021 Annual Meeting of the American Society of Hematology (ASH).
News
Dana-Farber/Boston Children’s Exceeds Expected Outcomes for Stem Cell Transplants
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center was ranked as one of 15 transplant centers in the country that performed above the expected survival rate, according to a new report.
News
Dana-Farber Researchers Present Findings at 2022 ASCO Genitourinary Cancers Symposium
Dana-Farber Cancer Institute researchers presented important research studies during the 2022 ASCO Genitourinary (GU) Cancers Symposium, that took place from February 17-19, both virtually and in-person in San Francisco.
News
A Case of Mistaken Identity: Researchers Unmask Cellular Source of Barrett’s Esophagus
Two recent studies by Dana-Farber Cancer Institute scientists correct a longstanding misconception about the origins of Barrett’s esophagus, and in doing so may point to new avenues of treatment or prevention to lower the risk of esophageal cancer.
Video
Dana-Farber’s Momentum of Discovery
William G. Kaelin Jr., MD won the Nobel Prize for discovering how cancer grows and multiplies by hijacking the body’s oxygen-sensing system, which led to a new class of oxygen-regulating drugs.
News
Genetic Testing, Precision Therapy Spell Success for Young Patient with Rare Syndrome
In a recent case study in the New England Journal of Medicine, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center describe how a drug targeting the genetic roots of the patient’s condition — an agent based on Nobel Prize-winning research by a Dana-Farber scientist — has caused new tumors in the patient to shrivel, her high blood pressure and headaches to ease, and her polycythemia to relent.
Symposium
2021 ASH Highlights
Review Dana-Farber Cancer Institute faculty highlights from the 63rd Annual Meeting of the American Society of Hematology (ASH).
News
Scientists Identify Potential Target in Ewing Sarcoma Cells
Investigators led by Dana-Farber Cancer Institute’s Kimberly Stegmaier, MD, have discovered that knocking out a protein regulator in Ewing sarcoma cells causes the tumor cells to die from an overdose of a cancer-promoting protein.
News
Immunotherapy Combination Shown to Benefit Some Patients with Non-Small Cell Lung Cancer Resistant to Single Immunotherapy
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent, results from a recent clinical trial show.
News
Venetoclax Added to Chemotherapy Improves Outcomes in Type of Leukemia
Adding the BCL-2 inhibitor drug venetoclax to a combination chemotherapy regimen significantly improved outcomes in Richter’s syndrome, a rare but deadly complication that develops in some patients with chronic lymphocytic leukemia (CLL), according to a study led by Dana-Farber investigators.
Symposium
2021 SABCS Highlights
Dana-Farber Cancer Institute faculty highlights from the 2021 San Antonio Breast Cancer Symposium.
News
Immunotherapy Combination Shows Significant Benefit for Patients with Advanced Melanoma
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients.